Literature DB >> 9528907

Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38.

T Bourne1, M Zukowska-Cooper, M R Salaman, M H Seifert, D A Isenberg.   

Abstract

Cells spontaneously secreting IgG or IgM (ISC) are present at a high level in the blood of patients with systemic lupus erythematosus (SLE). By use of magnetic-bead techniques, mononuclear cells from such patients and healthy donors were fractionated according to expression of CD19 or CD38 and the cell fractions were then cultured in the absence of added mitogen/antigen for 5/6 days. Supernatant IgG and IgM were determined and, in addition, in the CD38 experiments ISC were enumerated both before and after culture. Much of the immunoglobulin-producing capacity of unfractionated cells (UFC) from both donor groups was recovered in the CD19- fraction, and no immunoglobulin was produced by CD19+ cells suggesting, unexpectedly, that ISC were not expressing CD19. By contrast, CD38 fractionation resulted in nearly all ISC passing to the CD38+ fraction which produced levels of immunoglobulin approaching 50% that of UFC. On culture of CD38- cells there was a build up in the number of IgG and IgM ISC, this being particularly striking in the controls with numbers well in excess of those in UFC. Not all these new ISC became CD38+, but the maturation process was more efficient in the SLE patients. The possibility is discussed that the spontaneous response in the CD38- populations is due to removal of CD38+ natural killer (NK) cells. Removal of ISC that are present preculture is a helpful initial step in studying ISC generation in the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528907      PMCID: PMC1904880          DOI: 10.1046/j.1365-2249.1998.00533.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

Review 1.  CD38: a multi-lineage cell activation molecule with a split personality.

Authors:  F Malavasi; A Funaro; M Alessio; L B DeMonte; C M Ausiello; U Dianzani; F Lanza; E Magrini; M Momo; S Roggero
Journal:  Int J Clin Lab Res       Date:  1992

2.  Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation.

Authors:  S Funderud; B Erikstein; H C Asheim; K Nustad; T Stokke; H K Blomhoff; H Holte; E B Smeland
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

Review 3.  Multiple targets for brefeldin A.

Authors:  H R Pelham
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

4.  Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma.

Authors:  A Michael; J J Hackett; M Bennett; V Kumar; D Yuan
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

5.  Regulation of the secondary in vitro antibody response by endogenous natural killer cells: kinetics, isotype preference, and non-identity with T suppressor cells.

Authors:  C P Robles; S B Pollack
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

6.  Differentiation of human in vivo antigen-induced lymphoblastoid B cell precursors can be prevented by natural killer cells.

Authors:  A Garcia-Alonso; J A Brieva
Journal:  Clin Immunol Immunopathol       Date:  1990-10

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus.

Authors:  A Yabuhara; F C Yang; T Nakazawa; Y Iwasaki; T Mori; K Koike; H Kawai; A Komiyama
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

9.  Mechanism of spontaneous activation of B cells in patients with systemic lupus erythematosus. Analysis with anti-class II antibody.

Authors:  Y Tanaka; F Shirakawa; T Ota; H Suzuki; S Eto; U Yamashita
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

10.  Cytokine-independent progression of immunoglobulin production in vitro by B lymphocytes from patients with systemic lupus erythematosus.

Authors:  B K Pelton; M Speckmaier; W Hylton; J Farrant; A M Denman
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more
  6 in total

1.  Systemic onset juvenile rheumatoid arthritis presenting with absence of B lymphocytes.

Authors:  Hasibe Artac; Hayrullah Alp; Sevgi Keles; Ismail Reisli; Recep Tunc
Journal:  Rheumatol Int       Date:  2007-01-25       Impact factor: 2.631

2.  Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus.

Authors:  M Odendahl; R Keitzer; U Wahn; F Hiepe; A Radbruch; T Dörner; R Bunikowski
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

3.  Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.

Authors:  Shang-xue Yan; Xiao-mei Deng; Qing-tong Wang; Xiao-jing Sun; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

4.  A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.

Authors:  Hava Ben-David; Amir Sharabi; Reshmi Parameswaran; Heidy Zinger; Edna Mozes
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

5.  Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

Authors:  Amrie C Grammer; Rebecca Slota; Randy Fischer; Hanan Gur; Hermann Girschick; Cheryl Yarboro; Gabor G Illei; Peter E Lipsky
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

6.  Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity.

Authors:  Joan Wither; Yong-chun Cai; Sooyeol Lim; Tamara McKenzie; Nicole Roslin; Jaime O Claudio; Glinda S Cooper; Thomas J Hudson; Andrew D Paterson; Celia M T Greenwood; Dafna Gladman; Janet Pope; Christian A Pineau; C Douglas Smith; John G Hanly; Christine Peschken; Gilles Boire; Paul R Fortin
Journal:  Arthritis Res Ther       Date:  2008-09-10       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.